Sanuwave Health entered into Amendment No. 1 to its Credit Agreement, securing a waiver from lenders for any defaults related to the fixed charge coverage ratio for the twelve-month period ending September 30, 2026. The amendment imposes stricter covenants, requiring written consent for permitted acquisitions and equity repurchases, while lowering limits on other secured indebtedness and subsidiary investments from $500,000 to $250,000 each. The company also agreed to pay a $5,000 amendment fee. Sanuwave Health develops medical devices for the treatment of chronic pain.
